David Nierengarten
Stock Analyst at Wedbush
(3.92)
# 657
Out of 4,667 analysts
206
Total ratings
46.72%
Success rate
11.39%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMRX Chimerix | Reiterates: Outperform | $6 | $0.90 | +567.56% | 3 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $14 | $13.94 | +0.43% | 8 | Nov 18, 2024 | |
| APGE Apogee Therapeutics | Reiterates: Outperform | $87 | $44.40 | +95.95% | 2 | Oct 25, 2024 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $9.35 | +252.94% | 5 | Oct 25, 2024 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $20 | $3.37 | +494.35% | 2 | Oct 24, 2024 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $5 | $2.63 | +90.11% | 7 | Oct 22, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $27 → $37 | $26.94 | +37.37% | 6 | Oct 7, 2024 | |
| INZY Inozyme Pharma | Reiterates: Outperform | $15 | $2.66 | +463.91% | 6 | Sep 30, 2024 | |
| ANAB AnaptysBio | Reiterates: Outperform | $42 | $20.89 | +101.05% | 12 | Sep 26, 2024 | |
| NUVL Nuvalent | Maintains: Outperform | $99 → $115 | $92.53 | +24.29% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $10.18 | +126.04% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $8.73 | +129.10% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $20.28 | +97.24% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $27.17 | +65.62% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.00 | +150.00% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $11.05 | +62.90% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $63.72 | -10.55% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $1.30 | +284.62% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $519 → $560 | $588.56 | -4.85% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $21.04 | +61.59% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.07 | +62.87% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.76 | +13.64% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $9.15 | +9.29% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.61 | +206.51% | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.79 | +1,292.58% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $23.77 | +51.45% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $5 | $2.12 | +136.41% | 14 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $110 | $95.49 | +15.20% | 2 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.90 | +314.51% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.60 | +141.53% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $1.68 | $0.30 | +463.95% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $2.18 | +221.84% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $70 | $36.55 | +91.52% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $8.69 | +5,653.74% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $7.86 | +319.85% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $4 | $0.77 | +419.48% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $53 → $46 | $16.51 | +178.62% | 7 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $4.93 | +285.40% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $46.91 | +59.88% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 | $0.27 | +32,698.83% | 3 | Jan 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.62 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $5.37 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.40 | - | 3 | Nov 20, 2017 |
Chimerix
Nov 18, 2024
Reiterates: Outperform
Price Target: $6
Current: $0.90
Upside: +567.56%
Intellia Therapeutics
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $13.94
Upside: +0.43%
Apogee Therapeutics
Oct 25, 2024
Reiterates: Outperform
Price Target: $87
Current: $44.40
Upside: +95.95%
Immunome
Oct 25, 2024
Reiterates: Outperform
Price Target: $33
Current: $9.35
Upside: +252.94%
Perspective Therapeutics
Oct 24, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.37
Upside: +494.35%
Nuvation Bio
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.63
Upside: +90.11%
Scholar Rock Holding
Oct 7, 2024
Maintains: Outperform
Price Target: $27 → $37
Current: $26.94
Upside: +37.37%
Inozyme Pharma
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $2.66
Upside: +463.91%
AnaptysBio
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $20.89
Upside: +101.05%
Nuvalent
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $92.53
Upside: +24.29%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $10.18
Upside: +126.04%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $8.73
Upside: +129.10%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $20.28
Upside: +97.24%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $27.17
Upside: +65.62%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.00
Upside: +150.00%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $11.05
Upside: +62.90%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $63.72
Upside: -10.55%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.30
Upside: +284.62%
Jul 26, 2024
Maintains: Outperform
Price Target: $519 → $560
Current: $588.56
Upside: -4.85%
Jul 23, 2024
Maintains: Outperform
Price Target: $30 → $34
Current: $21.04
Upside: +61.59%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.07
Upside: +62.87%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.76
Upside: +13.64%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $9.15
Upside: +9.29%
May 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.61
Upside: +206.51%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.79
Upside: +1,292.58%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $23.77
Upside: +51.45%
May 10, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $2.12
Upside: +136.41%
Apr 26, 2024
Reiterates: Outperform
Price Target: $110
Current: $95.49
Upside: +15.20%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.90
Upside: +314.51%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.60
Upside: +141.53%
Mar 19, 2024
Maintains: Neutral
Price Target: $3 → $1.68
Current: $0.30
Upside: +463.95%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.18
Upside: +221.84%
Feb 26, 2024
Maintains: Outperform
Price Target: $60 → $70
Current: $36.55
Upside: +91.52%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $8.69
Upside: +5,653.74%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $7.86
Upside: +319.85%
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $0.77
Upside: +419.48%
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $16.51
Upside: +178.62%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $4.93
Upside: +285.40%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $46.91
Upside: +59.88%
Jan 17, 2020
Downgrades: Neutral
Price Target: $90
Current: $0.27
Upside: +32,698.83%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $2.62
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $5.37
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $14.40
Upside: -